Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
View Patent ↗The present invention provides anti-CD20 antibody fragments for use as in vivo imaging probes and as therapeutic moieties for the diagnosis and treatment of NHL.
1. A method of diagnosing a CD20-expressing cancer in a human or mouse subject, the method comprising the steps of:
a) administering to the subject an anti-CD20 antibody fragment comprising the amino acid sequence of SEQ ID NO: 2 linked to a detectable moiety; and
b) detecting the moiety linked to the antibody fragment in the subject;
wherein detection of the moiety diagnoses a CD20-expressing cancer in the subject.
2. The method of claim 1 , wherein the cancer is a non-Hodgkin's lymphoma (NHL).
3. The method of claim 1 , wherein the moiety linked to the antibody fragment is detected using PET or SPECT.
4. The method of claim 1 , wherein the antibody fragment is further linked to a nanosensor.
5. The method of claim 1 , the detectable moiety is 64Cu, 99Tc, 111In, 123I, 124I or 131I.